Financial Data and Key Metrics Changes - The company ended Q4 2021 with $401.3 million in cash, cash equivalents, and short-term investments, a decrease from $411.6 million as of December 31, 2020 [40] - Total revenue for Q4 2021 was $839,000, down from $5.6 million in Q4 2020, and for the full year, revenue was $1.8 million compared to $7.4 million in 2020 [40] - Total operating expenses increased to $106.3 million for Q4 2021 and $303 million for the full year, compared to $34.9 million and $131.5 million for the same periods in 2020 [41] - The net loss for Q4 2021 was $106.9 million or $0.50 per share, and for the full year, it was $303.7 million or $1.45 per share, compared to a net loss of $24.3 million or $0.14 per share in Q4 2020 [42] Business Line Data and Key Metrics Changes - The company completed full enrollment of 192 participants for the Phase 2 trial of INO-4700 against MERS, which is being conducted in Jordan, Lebanon, and Kenya [24] - Full enrollment was also achieved for the Phase 1b trial of INO-4500 for Lassa fever, with 220 participants enrolled in Ghana [25] - Enrollment of 46 participants was completed for the Phase 1b trial of INO-4201 for Ebola [26] Market Data and Key Metrics Changes - The company noted that while over 63% of the global population has received at least one vaccine dose, first dose vaccination rates in certain countries remain below 12% [10] - The company highlighted the ongoing need for improved access to vaccines and boosters globally, particularly in low to middle-income countries [10] Company Strategy and Development Direction - The company plans to seek regulatory approval to amend the primary endpoint for the Phase 3 INNOVATE trial from prevention of all symptomatic disease to prevention of severe disease [12] - The company is evaluating the feasibility of an additional ex-U.S. heterologous boost trial for INO-4800, comparing it to previously approved vaccines [15] - A memorandum of understanding was signed with Colombia's Ministry of Health to explore collaboration in developing and producing vaccines and biopharmaceuticals locally [38] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of T cell responses in protecting against severe disease and the durability of vaccine protection [11][23] - The company expressed confidence in the INO-4800 vaccine's ability to maintain T cell responses against various COVID-19 variants, including Omicron [56] - Management is optimistic about the potential of their DNA medicines platform to address global health needs as COVID-19 transitions from a pandemic to an endemic stage [20] Other Important Information - The company completed the 52-week safety follow-up of REVEAL1 participants, showing VGX-3100 remained well tolerated [31] - The WHO selected INO-4800 for the Solidarity Trial Vaccines, a large international randomized control trial [20] Q&A Session Summary Question: Will biomarker data be used in the REVEAL2 trials? - Management confirmed that they are advancing biomarker development with QIAGEN to identify signatures that predict responses to VGX-3100 [50][51] Question: How is the company addressing the INNOVATE trial amid Omicron? - Management stated that they are proactively seeking to amend the trial's primary endpoint and are confident in the vaccine's T cell response against severe disease [55][56] Question: What are the expectations for regulatory approval steps? - Management outlined that amending the primary endpoint involves modifying the protocol and obtaining approvals from regulatory bodies [62] Question: When will results from the Phase 2 trial of the MERS vaccine be reported? - Management indicated that results are expected by Q3 of the current year as enrollment is ongoing [88]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Delaware 33-0969592 (I.R.S. Employer Identification No.) REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (267) 440-4200 SECURITIES REGISTERED PURSUANT TO SECTION 12(B) ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2021 Earnings Conference Call November 9, 2021 4:30 PM ET CompanyParticipants Joseph Kim – President and CEO Ben Matone – Senior Director of Investor Relations Peter Kies – Chief Financial Officer Jackie Shea – Chief Operating Officer Laurent Humeau – Chief Scientific Office Jeffrey Skolnik – Senior Vice President of Clinical Development Anza Mammen – Senior Vice President of Clinical Development Kate Broderick – Senior Vice President of Research and Development ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) If an emerging growth company, indicate by check ...

Powering a New Decade of DNA Medicines September 2021 :INO Forward-Looking Statements This presentation includes statements that are, or may be deemed, "forward-looking statements,"" within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management are forward-lo ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Cantor 2021 Global Healthcare Conference September 30, 2021 12:40 PM ET Company Participants Joseph Kim - President & Chief Executive Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Charles Duncan Hello, welcome to the Cantor Global Healthcare Conference for 2021. My name is Charles Dunkin and I'm a Managing Director and Senior Biotechnology analysts with the firm. And today is day four of the conference, and it's been quite a conference, and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction of i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) (State or other jurisdiction of incorporation or organi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction of incor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction of ...